Personalized Radiation Therapy for GBM

Conditions

Glioblastoma

Brief summary

The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. Toxicity, patterns of recurrence, and overall median survival will be measured as secondary endpoints. Adverse events will be monitored.

Akbari H, Mohan S, Liu F, Jiang C, Fathi Kazerooni A, Berger M, Rathore S, Bilello M, Sako C, Garcia J, Brem S, Bakas S, Mamourian E, Pepin A, James P, Dorsey J, Singh A, Parker D, Verma R, Cao Q, Bagley SJ, Desai A, O'Rourke DM, Shinohara RT, Nasrallah MP, Teo BK, Kurtz G, Shukla G, Alonso-Basanta M, Lustig RA, Davatzikos C.

2026-05-13

10.1038/s41467-026-72545-y

CTNI-31. AI-GUIDED PERSONALIZED PRECISION RADIATION THERAPY WITH TARGETED DOSE ESCALATION FOR NEWLY DIAGNOSED GLIOBLASTOMA: A MATCHED-CONTROL STUDY

Hamed Akbari, Suyash Mohan, Anahita Fathi Kazerooni, Saima Rathore, Michel Bilello et al. (31 authors)

Neuro-Oncology2024-11-011 citations

10.1093/neuonc/noae165.0398

CTNI-56. FEASIBILITY AND EFFICACY OF AI-GUIDED PERSONALIZED PRECISION RADIATION THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA: A MATCHED-CONTROL STUDY

Hamed Akbari, Suyash Mohan, Anahita Fathi Kazerooni, Michel Bilello, Chiharu Sako et al. (30 authors)

Neuro-Oncology2023-11-012 citations

10.1093/neuonc/noad179.0338

Interventions

RADIATIONRadation Therapy

Personalized Radiation Therapy

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen * Age 18 or older * Ability to give signed informed consent * Karnofsky Performance Status (KPS) at least 70

Exclusion criteria

* Placement of Gliadel wafers * Participation in another investigational trial * Active treatment of another malignancy

Design outcomes

Primary

Measure	Time frame
Adverse Events	2 years

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORMichelle Alonso-Basanta, MD

Abramson Cancer Center at Penn Medicine

Outcome results

None listed